Publishing house Hearst is pushing into precision medicine with a $75 million investment in M2Gen, the informatics subsidiary of Moffitt Cancer Center.
Swiss genomic analytics and AI firm Sophia Genetics has closed on a $30 million Series D round, led by new investor Balderton Capital.
With the cash, WuXi NextCode will build out its AI and deep learning, seek partnerships in precision medicine and diagnostics, and commercialize genomic tests.
The company, Gencove, was founded by the developers of a consumer-focused, smartphone-accessible genetic testing program launched in beta as Seeq.
Genoox, which provides data analytics for integrating genomic sequencing information into clinical workflow, said the investment was led by two Israeli VC firms.
GeneNews has signed a binding agreement with multinational private equity firm Milost Global for up to $10 million in equity and debt financing.
SOL will help Personal Genomics to further develop its research projects and implement its new facility dedicated to DNA sequencing.
Dell Technologies Capital, newly out of stealth, invested in Edico Genome because it believes whole-genome sequencing is almost ready to take off on a wide scale.
Israel-based BiomX uses a proprietary microbiome modulation technology to discover and develop microbiome-based therapeutics.
wiss genomic data management company BC Platforms seeks to add a clinical component to its existing software this year.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.